trial

A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia

NCTId NCT07550387
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 363 (actual)
Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.
Primary completion 2026-01-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
363 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-05-23
Primary completion
2026-01-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
HS-10380 Low DoseHS-10380 Medium doseHS-10380 High DoseAripiprazole

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.Lead Sponsor

Sites

1 total
Shanghai, China

Linked catalysts

1
A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults Wit — primary completion2026-01-02

Facts & assertions

4 sourced
Enrollment
363
Phase
PHASE2
Primary Completion Date
2026-01-02
Status
COMPLETED
relationships
The graph out of here
drug
HS-10380 Low Dose
drug
HS-10380 Medium dose
drug
HS-10380 High Dose
drug
Aripiprazole
drug
lead_sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
company
indication
Schizophrenia
indication
SCHIZOPHRENIA 1 (Disorder)
indication